DCPH - Blueprint Medicines Appears Increasingly Competitive In RET-Mutated NSCLC
Idea Slides
Introduction
RET mutations are seen in ~2% of NSCLCs. Currently, there are no FDA-approved treatments for RET-mutated NSCLC. Multi-targeted drugs have been tested in these patients, but without much success.
RET-targeted therapies like Blueprint Medicines' (BPMC) and Loxo Oncology's (LOXO) provide substantial therapeutic differentiation and opportunity.
Blueprint appears increasingly competitive in NSCLC
Previously, Blueprint had reported an ORR of 50% in 2L NSCLC, which was considerably inferior to Loxo's numbers.
"In a preliminary analysis of an ongoing phase 1 study which included 19 patients with NSCLC with RET fusions,